Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Healthtrust
Fish and Richardson
Covington
Express Scripts
Fuji
Teva
Argus Health
US Department of Justice

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020131

« Back to Dashboard

NDA 020131 describes PROHANCE, which is a drug marketed by Bracco and is included in two NDAs. It is available from one supplier. Additional details are available on the PROHANCE profile page.

The generic ingredient in PROHANCE is gadoteridol. One supplier is listed for this compound. Additional details are available on the gadoteridol profile page.
Summary for 020131
Tradename:PROHANCE
Applicant:Bracco
Ingredient:gadoteridol
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 020131
Suppliers and Packaging for NDA: 020131
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PROHANCE gadoteridol INJECTABLE;INJECTION 020131 NDA BRACCO DIAGNOSTICS INC 0270-1111 0270-1111-01 5 VIAL, SINGLE-DOSE in 1 BOX (0270-1111-01) > 10 mL in 1 VIAL, SINGLE-DOSE
PROHANCE gadoteridol INJECTABLE;INJECTION 020131 NDA BRACCO DIAGNOSTICS INC 0270-1111 0270-1111-03 5 VIAL, SINGLE-DOSE in 1 BOX (0270-1111-03) > 20 mL in 1 VIAL, SINGLE-DOSE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength279.3MG/ML
Approval Date:Nov 16, 1992TE:RLD:Yes

Expired US Patents for NDA 020131

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bracco PROHANCE gadoteridol INJECTABLE;INJECTION 020131-001 Nov 16, 1992 ➤ Subscribe ➤ Subscribe
Bracco PROHANCE gadoteridol INJECTABLE;INJECTION 020131-001 Nov 16, 1992 ➤ Subscribe ➤ Subscribe
Bracco PROHANCE gadoteridol INJECTABLE;INJECTION 020131-001 Nov 16, 1992 ➤ Subscribe ➤ Subscribe
Bracco PROHANCE gadoteridol INJECTABLE;INJECTION 020131-001 Nov 16, 1992 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Baxter
Farmers Insurance
QuintilesIMS
McKesson
Citi
Deloitte
Accenture
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot